139 related articles for article (PubMed ID: 15886328)
1. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
[TBL] [Abstract][Full Text] [Related]
2. CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy.
Walter RB; Gooley TA; van der Velden VH; Loken MR; van Dongen JJ; Flowers DA; Bernstein ID; Appelbaum FR
Blood; 2007 May; 109(10):4168-70. PubMed ID: 17227830
[TBL] [Abstract][Full Text] [Related]
3. Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.
Duong HK; Sekeres MA
Clin Interv Aging; 2009; 4():197-205. PubMed ID: 19503782
[TBL] [Abstract][Full Text] [Related]
4. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia.
Cortes JE; de Lima M; Dombret H; Estey EH; Giralt SA; Montesinos P; Röllig C; Venditti A; Wang ES
J Hematol Oncol; 2020 Oct; 13(1):137. PubMed ID: 33059764
[TBL] [Abstract][Full Text] [Related]
5. Prior Gemtuzumab Ozogamicin Exposure in Adults with Acute Myeloid Leukemia Does Not Increase Hepatic Veno-Occlusive Disease Risk after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Ho VT; Martin AS; Pérez WS; Steinert P; Zhang MJ; Chirnomas D; Hoang CJ; Loberiza FR; Saber W
Biol Blood Marrow Transplant; 2020 May; 26(5):884-892. PubMed ID: 31891815
[TBL] [Abstract][Full Text] [Related]
6. Gemtuzumab ozogamicin for relapsed or primary refractory acute myeloid leukemia in children-the Polish Pediatric Leukemia and Lymphoma Study Group experience.
Pawinska-Wasikowska K; Czogala M; Skoczen S; Surman M; Rygielska M; Ksiazek T; Pac A; Wieczorek A; Skalska-Sadowska J; Samborska M; Wachowiak J; Chaber R; Tomaszewska R; Szczepanski T; Zielezinska K; Urasinski T; Moj-Hackemer M; Kalwak K; Kozlowska M; Irga-Jaworska N; Balwierz W; Bukowska-Strakova K
Front Immunol; 2023; 14():1268993. PubMed ID: 38187390
[TBL] [Abstract][Full Text] [Related]
7. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review.
Collados-Ros A; Muro M; Legaz I
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38255313
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic plasma exchange as an intervention for gemtuzumab ozogamicin impaired hemoglobin scavenging: A case and systematic review.
Adkins BD; Noland DK; Slone T; Sadanand A
J Clin Apher; 2024 Jun; 39(3):e22116. PubMed ID: 38647036
[TBL] [Abstract][Full Text] [Related]
10. First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome.
Narayan R; Piérola AA; Donnellan WB; Yordi AM; Abdul-Hay M; Platzbecker U; Subklewe M; Kadia TM; Alonso-Domínguez JM; McCloskey J; Bradford K; Curtis M; Daskalakis N; Guttke C; Safer K; Hiebert B; Murphy J; Li X; Duchin K; Esteban D
Clin Transl Sci; 2024 Mar; 17(3):e13742. PubMed ID: 38494922
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.
Satomaa T; Pynnönen H; Aitio O; Hiltunen JO; Pitkänen V; Lähteenmäki T; Kotiranta T; Heiskanen A; Hänninen AL; Niemelä R; Helin J; Kuusanmaki H; Vänttinen I; Rathod R; Nieminen AI; Yatkin E; Heckman CA; Kontro M; Saarinen J
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38561023
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine and gemtuzumab ozogamicin as post-transplant maintenance therapy for high-risk hematologic malignancies.
Kaito S; Najima Y; Sadato D; Hirama C; Kishida Y; Nagata A; Konishi T; Yamada Y; Kurosawa S; Yoshifuji K; Shirane S; Shingai N; Toya T; Shimizu H; Haraguchi K; Kobayashi T; Harada H; Okuyama Y; Harada Y; Doki N
Bone Marrow Transplant; 2024 May; ():. PubMed ID: 38783125
[TBL] [Abstract][Full Text] [Related]
13. Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Ravandi F; Subklewe M; Walter RB; Vachhani P; Ossenkoppele G; Buecklein V; Döhner H; Jongen-Lavrencic M; Baldus CD; Fransecky L; Pardee TS; Kantarjian H; Yen PK; Mukundan L; Panwar B; Yago MR; Agarwal S; Khaldoyanidi SK; Stein A
Leuk Lymphoma; 2024 May; ():1-11. PubMed ID: 38712673
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia: focus on novel therapeutic strategies.
Lin TL; Levy MY
Clin Med Insights Oncol; 2012; 6():205-17. PubMed ID: 22654526
[TBL] [Abstract][Full Text] [Related]
15. Late-onset
Jaramillo S; Scherer M; Szu-Tu C; Beneyto-Calabuig S; Müller-Tidow C; Schlenk RF; Hundemer M; Velten L; Pabst C
Haematologica; 2024 May; ():. PubMed ID: 38813731
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.
Oya S; Ozawa H; Nakamura T; Mori A; Ochi S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
Int J Hematol; 2024 Jun; ():. PubMed ID: 38853211
[TBL] [Abstract][Full Text] [Related]
17. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
Larson RA; Sievers EL; Stadtmauer EA; Löwenberg B; Estey EH; Dombret H; Theobald M; Voliotis D; Bennett JM; Richie M; Leopold LH; Berger MS; Sherman ML; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR
Cancer; 2005 Oct; 104(7):1442-52. PubMed ID: 16116598
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia.
Khan N; Hantel A; Knoebel RW; Artz A; Larson RA; Godley LA; Thirman MJ; Liu H; Churpek JE; King D; Odenike O; Stock W
Leuk Lymphoma; 2017 Sep; 58(9):1-7. PubMed ID: 28278716
[TBL] [Abstract][Full Text] [Related]
19. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group.
Taksin AL; Legrand O; Raffoux E; de Revel T; Thomas X; Contentin N; Bouabdallah R; Pautas C; Turlure P; Reman O; Gardin C; Varet B; de Botton S; Pousset F; Farhat H; Chevret S; Dombret H; Castaigne S
Leukemia; 2007 Jan; 21(1):66-71. PubMed ID: 17051246
[TBL] [Abstract][Full Text] [Related]
20. Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.
Niktoreh N; Lerius B; Zimmermann M; Gruhn B; Escherich G; Bourquin JP; Dworzak M; Sramkova L; Rossig C; Creutzig U; Reinhardt D; Rasche M
Haematologica; 2019 Jan; 104(1):120-127. PubMed ID: 30093401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
